You are here: Industry Insights > Cancer

News List

AbbVie’s experimental cancer drug hits wall in clinical study pharmafile
April 21, 2017
AbbVie have released that two Phase 3 trials of its experimental cancer drug, veliparib, missed both of their primary...
AbbVie’s PARP inhibitor fails in PhIII trials pharmatimes
April 21, 2017
AbbVie’s experimental PARP inhibitor veliparib has failed to meet key targets in two late-stage studies testing its potential in lung and breast cancer.
IriSys Doubles Contract with NCI for Mfg. Clinical Trial Materials contractpharma
April 21, 2017
The contract is for development and production of new therapeutic agents for use in clinical trials supported by NCI
Targovax initiates clinical immunotherapy trial to treat RAS-mutated cancer europeanpharmaceuticalreview
April 21, 2017
Targovax, a clinical stage company focused on developing immune-oncology therapies to target solid tumours, has recruited the first patient in an exploratory Phase Ib clinical trial of TG02 in patients with locally recurrent RAS-mutated rectal cancer sche
Cancer Research UK, CPF and NCI partner to develop tests to analyse RAS inhibitors pharmaceutical-technology
April 20, 2017
Cancer Research UK and the Cancer Research Technology Pioneer Fund (CPF) National Cancer Institute (NCI), US, have ...
Roche's drug scores expanded FDA indication in advanced bladder cancer pharmafile
April 19, 2017
Roche’s Genentech has revealed that its immunotherapy drug Tecentriq (atezolizumab) is now enjoying an expanded ...
CR UK, CRT Pioneer Fund and the NCI link on RAS pharmatimes
April 19, 2017
Cancer Research UK and the Cancer Research Technology Pioneer Fund (CPF) are committing £2.5 million in collaboration...
BMS links with Apexigen to test cancer immunotherapy combo pharmatimes
April 14, 2017
Bristol-Myers Squibb and Apexigen are to test a combination of Opdivo and the latter’s investigational compound APX005M in patients with advanced solid tumours.
NICE’s draft guidance ignores recommendation of Opdivo to treat cancer, Bristol-Myers Squibb says pharmaceutical-technology
April 14, 2017
US-based Bristol-Myers Squibb has confirmed that the National Institute for Health and Care Excellence (NICE) has issued draft guidance that ignores recommendation of investigational cancer immunotherapy Opdivo (nivolumab).
Cancer can be diagnosed by Google's artificial intelligence biospectrumasia
April 14, 2017
The system is able to scan samples to determine whether or not tissues are cancerous

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page